1.Exploration of the Cultivation of Medical Humanistic Spirit under the Perspective of Healthy China
Yuanlin DAI ; Yi LONG ; Hongjiang JIAN
Chinese Medical Ethics 2018;31(6):762-766
Through the comparison of the research status of medical humanistic spirit cultivation at home and abroad , this paper found that the main challenges facing by the cultivation of medical humanistic spirit in China were as the following three aspects:the medical humanities curriculum was not reasonable;the medical students were not fully aware of medical humanistic spirit;people were laying emphasis on imparting knowledge, and neglecting the practice of medical humanities. According to the problems facing by the cultivation of medical humanistic spirit in China at the present stage, taking the strategic research of Healthy China as an opportunity, this paper analyzed the influence of Healthy China strategy on the cultivation of medical humanistic spirit, and put forward the path of the cultivation of medical humanistic spirit from the perspective of Healthy China.
2.Ethical considerations for drug clinical trials
Yue ZHAO ; Jian JIANG ; Hongjiang ZHANG
Chinese Medical Ethics 2024;37(8):890-895
In the process of drug clinical trials,while proposing positive countermeasures to the legal and practical issues they raise,more attention should be paid to the ethical aspects of their responsibility,such as loss of the subjects'sense of personal responsibility,insufficient supervision by regulatory bodies,responsible parties of researcher ignoring the spirit of the contract,and conflicts between professional requirements and individual requirements.In response to the above issues,based on the principle of responsible ethics,specific countermeasures were proposed,such as cultivating personal awareness of responsibility ethics,strengthening the standards of industry ethical review,improving informed consent compensation clauses,and cultivating research subjects'awareness of responsibility ethics,thus to enhance the protection of the rights and interests of drug clinical trials'subjects,as well as to protect the subjects'rights and interests of life and health.